Strong Revenue Growth and Raised Guidance
Revenue of $78 million in Q1 2026, up 42% year-over-year. Company raised full-year revenue guidance to $322M–$330M (from $312M–$322M); midpoint implies ~25% growth year‑over‑year.
Membership Milestone and Enrollment Momentum
Total members crossed 1 million, ending Q1 at 1,025,000 (up 51% YoY). Net new members in Q1 were 139,000 vs 107,000 in Q1 2025. Omada-led outreach and enrollment experience enhancements drove higher conversion and multi-condition penetration.
Improved Profitability and Margins
GAAP gross profit was $49M with GAAP gross margin of 62% (up from 58% YoY). Non-GAAP gross margin was 64% (up from 60% YoY). GAAP net loss narrowed to $3M (vs $9M in Q1 '25) and adjusted EBITDA was $1M (improvement of $5M YoY). Full-year adjusted EBITDA guidance raised to $14M–$20M (from $7M–$15M).
Stronger Operational Levers from AI and Product
AI is embedded across care delivery, engineering and operations, accelerating product velocity and driving care-team productivity. Nutrition/AI features (Meal Map) produced ~16% relative lift in weekly active meal tracking among new members.
Expanded Commercial Reach and PBM Relationships
Omada now has relationships with the three largest PBMs, joined Optum Rx's Weight Engage portfolio and Eli Lilly's Employer Connect, expanding channels for GLP-1 prescribing and wraparound care and increasing access to commercially insured lives.
Clinical Evidence and GLP-1 Traction
GLP-1 Care Track supported more than 150,000 members as of end-2025. New clinical analysis: members on Omada's GLP-1 Care Track lost on average 1.8x total weight and twice the body fat vs control over 12 weeks, and showed durable outcomes (0.8% average weight change one year after stopping with Omada support vs 11–12% regain in trials without support). Omada cites 30 peer‑reviewed studies.
Healthy Balance Sheet and Debt-Free Position
Ended Q1 with $212M in cash and cash equivalents and no debt after early repayment of term loan, supporting runway for continued investment.